Menzies School of Health Research, Darwin, NT, Australia.
University of Melbourne, Melbourne, VIC, Australia.
Med J Aust. 2015 Jun 1;202(10):S78-84. doi: 10.5694/mja15.00205.
To examine the use of nicotine replacement therapy (NRT) and the stop-smoking medicines (SSMs) varenicline and bupropion in a national sample of Aboriginal and Torres Strait Islander smokers and recent ex-smokers.
DESIGN, SETTINGS AND PARTICIPANTS: The Talking About The Smokes (TATS) project used a quota sampling design to recruit a nationally representative sample of 1721 smokers and ex-smokers who had quit ≤ 12 months before from communities served by 34 Aboriginal community-controlled health services and one community in the Torres Strait. Baseline surveys were conducted from April 2012 to October 2013. These were compared with 1017 daily smokers from the general Australian population surveyed by the International Tobacco Control Policy Evaluation Project (ITC Project) from July 2010 to May 2011.
Past and intended use of NRT and SSMs, duration of use, and whether participants thought NRT and SSMs help smokers to quit.
Compared with other daily Australian smokers, lower proportions of Aboriginal and Torres Strait Islander daily smokers had ever used any NRT or SSMs (TATS, 37% v ITC, 58.5%) or used them in the past year (TATS, 23% v ITC, 42.1%). Nicotine patches were most commonly used by Aboriginal and Torres Strait Islander smokers and recent ex-smokers (24%), followed by varenicline (11%) and nicotine gum (10%); most (74%) had got their last NRT at no cost. Among dependent Aboriginal and Torres Strait Islander daily smokers, those who were more socioeconomically advantaged were more likely than the disadvantaged to have used NRT or SSMs. Similar proportions of Aboriginal and Torres Strait Islander daily smokers and other Australian daily smokers said that NRT or SSMs help smokers to quit (TATS, 70% v ITC, 74.2%). Dependent Aboriginal and Torres Strait Islander smokers who had previously used NRT or SSMs were more likely to believe they help in quitting and to intend to use them in the future.
Aboriginal and Torres Strait Islander daily smokers, particularly those who are most disadvantaged, are less likely to have used NRT or SSMs than other Australian daily smokers. Some of the barriers to use, including cost, are being overcome, but further improvements are possible.
在全国范围内的原住民和托雷斯海峡岛民吸烟者和近期戒烟者样本中，调查尼古丁替代疗法（NRT）和戒烟药物（SSM）伐伦克林和安非他酮的使用情况。
设计、地点和参与者：“谈论吸烟”（TATS）项目采用配额抽样设计，从 34 个原住民社区控制的卫生服务机构和托雷斯海峡的一个社区中招募了 1721 名在 12 个月内戒烟的吸烟者和戒烟者，这些人是在社区内招募的。基线调查于 2012 年 4 月至 2013 年 10 月进行。这些调查结果与 2010 年 7 月至 2011 年 5 月期间，国际烟草控制政策评估项目（ITC 项目）对来自一般澳大利亚人群的 1017 名每日吸烟者进行的调查结果进行了比较。
过去和计划使用 NRT 和 SSM、使用时间以及参与者认为 NRT 和 SSM 是否有助于吸烟者戒烟。
与其他澳大利亚每日吸烟者相比，原住民和托雷斯海峡岛民每日吸烟者使用过任何 NRT 或 SSM（TATS，37% v ITC，58.5%）或过去一年使用过（TATS，23% v ITC，42.1%）的比例较低。尼古丁贴片是原住民和托雷斯海峡岛民吸烟者和近期戒烟者最常使用的（24%），其次是伐伦克林（11%）和尼古丁口香糖（10%）；大多数人（74%）以免费的方式获得了他们的最后一次 NRT。在依赖的原住民和托雷斯海峡岛民每日吸烟者中，那些社会经济地位较高的人比处境不利的人更有可能使用 NRT 或 SSM。原住民和托雷斯海峡岛民每日吸烟者和其他澳大利亚每日吸烟者中，有相似比例的人表示 NRT 或 SSM 有助于吸烟者戒烟（TATS，70% v ITC，74.2%）。曾经使用过 NRT 或 SSM 的依赖的原住民和托雷斯海峡岛民吸烟者更有可能相信它们有助于戒烟，并打算在未来使用它们。
原住民和托雷斯海峡岛民每日吸烟者，特别是那些处境最不利的人，使用 NRT 或 SSM 的比例低于其他澳大利亚每日吸烟者。一些使用障碍，包括成本，正在得到克服，但仍有进一步改进的空间。
